This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B20.8 (HIV disease resulting in other infectious and parasitic diseases) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV disease resulting in other infectious and parasitic diseases; AIDS with other specified infections |
| C. Adult onset | Likelihood of onset in adulthood: Very high — Opportunistic infections due to HIV infection occur mainly in adults whose immunosuppression has progressed several years after infection. B20.8 includes other opportunistic infections not specified in B20.0-B20.7 (e.g., isosporiasis, Strongyloides hyperinfection, microsporidiosis, non-tuberculous mycobacteria other than MAC), and is diagnosed in adults at the AIDS stage. |
| 1. History | After the AIDS definition was established, various opportunistic infection pathogens were discovered and reported one after another. Isospora, Strongyloides hyperinfection, microsporidia, non-tuberculous mycobacteria, and others were added as AIDS-defining opportunistic infections. |
| 2. Causes | Due to HIV-induced impairment of cell-mediated immunity, various opportunistic infections occur, including Isospora, Strongyloides, microsporidia, Salmonella bacteremia, non-tuberculous mycobacteria, and visceral Leishmania. |
| 3. Genetics | Not a hereditary disease. Host genetic factors (CCR5 polymorphism, HLA type, innate immunity-related genes) influence HIV progression and susceptibility to opportunistic infections. The genetic characteristics of each opportunistic pathogen determine virulence. |
| 4. General epidemiology | Opportunistic infections included in B20.8 are highly frequent in sub-Saharan Africa, South Asia, and Southeast Asia. Isosporiasis is common in patients with HIV in tropical and subtropical regions, and Strongyloides hyperinfection is reported as an AIDS complication in tropical parasite-endemic areas. |
| 5. Pathophysiology | HIV-induced decline in CD4+ T-cell and macrophage function → collapse of intestinal mucosal immunity → opportunistic intestinal parasitic and bacterial infections → in Strongyloides hyperinfection, destruction of the intestinal wall causes bacterial bacteremia. |
| 6. Symptoms | Main symptoms are chronic diarrhea, malabsorption, weight loss, abdominal pain, and fever. Strongyloides hyperinfection may be accompanied by sepsis, gram-negative bacteremia, and meningitis. Recurrent high fever in Salmonella bacteremia. |
| 7. Signs | Weight loss, hypoalbuminemia, diarrheal dehydration, abdominal distension, fever. In Strongyloides hyperinfection, findings of multiple organ failure and septic shock are possible. |
| 8. Screening | Regular monitoring of the CD4 count. Strongyloides serologic or stool testing in patients with HIV from Strongyloides-endemic areas. Include parasite testing in patients with HIV who have a history of visiting tropical regions. |
| 9. Diagnosis | Direct stool examination (ova and larvae), stool culture, blood culture, serum antibody test, small-bowel endoscopy and biopsy tissue examination. Microsporidia are diagnosed by electron microscopy or special stains (Modified trichrome). |
| 10. Treatment | Immune recovery by early initiation of ART. Isospora: TMP-SMX. Strongyloides: ivermectin (extended treatment duration for hyperinfection). Salmonella bacteremia: long-term fluoroquinolone treatment. Microsporidia: albendazole (Encephalitozoon) or fumagillin (Enterocytozoon). |
| 11. Prognosis | Mortality from Isospora and Strongyloides hyperinfection is high without treatment. Most cases are treatable after CD4 recovery with ART. Sepsis complicating Strongyloides hyperinfection has high mortality. |
| 12. Prevention | Maintain CD4 with ART. TMP-SMX for prevention of Isospora. In persons from Strongyloides-endemic areas, screening and prophylactic ivermectin before steroid use. Food and water hygiene management. |
| 13. References | OI guidelines (DHHS 2024) and 9 others |
Since 1981, when HIV/AIDS was first recognized, the spectrum of AIDS-related opportunistic infection pathogens has continued to expand. Initially, Pneumocystis pneumonia, Kaposi sarcoma, cryptococcal meningitis, and CMV infection were recognized as the main AIDS-defining opportunistic infections, but later a wider variety of opportunistic infection pathogens began to be reported in immunocompromised patients with HIV around the world.
Isospora (Cystoisospora belli, formerly Isospora belli) was included in the CDC's AIDS-defining opportunistic infections in 1984. This coccidian protozoan causes mild, self-limited diarrhea in immunocompetent persons, but causes chronic, intractable diarrhea and severe malabsorption in patients with HIV with low CD4 counts. It has been reported commonly in patients with HIV in tropical and subtropical regions such as Haiti, Africa, and South Asia.
Intestinal microsporidia (Microsporidia) have been recognized as a cause of chronic diarrhea in patients with HIV since 1985. Initially, diagnosis was difficult without electron microscopy, but with the development of special staining methods and PCR in the 1990s, Enterocytozoon bieneusi and Encephalitozoon intestinalis were identified as the main pathogenic species.
It has long been known that Strongyloides (Strongyloides stercoralis) hyperinfection syndrome follows a fatal course in the immunocompromised state, and cases have been reported in the context of HIV/AIDS since the 1980s-90s. In particular, it has been confirmed that Strongyloides hyperinfection frequently occurs when corticosteroids are used in patients with HIV from tropical and subtropical regions.
Salmonella bacteremia (non-typhoidal Salmonella bacteremia) is a characteristic opportunistic infection that recurs in patients with HIV, and was included in the CDC's AIDS definition in 1987. The risk of non-typhoidal Salmonella bacteremia in patients with HIV is 100 to 300 times higher than in persons with normal immunity, and in the pre-ART era recurrent bacteremia had significance as an AIDS-defining illness. The B20.8 code encompasses various other infectious and parasitic diseases that are not explicitly included in the subcodes of B20 (B20.0-B20.7).
The causes of B20.8 are 'other' opportunistic infection pathogens that occur against a background of progressive immunosuppression caused by HIV. It includes opportunistic infections not classified under B20.0 (Mycobacterium tuberculosis), B20.1 (Salmonella), B20.2 (other bacteria), B20.3 (Pneumocystis), B20.4 (Candida), B20.5 (other fungi), B20.6 (mycobacteria), and B20.7 (multiple infections).
Isosporiasis (Cystoisospora belli): A coccidian protozoan transmitted through contaminated food and water; in patients with HIV with CD4 <200/μL it causes chronic diarrhea and malabsorption syndrome. It is common in tropical and subtropical regions; it is self-limited in immunocompetent persons but persists without treatment in patients with HIV. Microsporidiosis: Enterocytozoon bieneusi, Encephalitozoon intestinalis, and others cause intestinal infection, leading to chronic diarrhea and malabsorption. Biliary tract infection and ocular infection are also possible. Strongyloides hyperinfection: A hyperinfection syndrome in which Strongyloides larvae penetrate the intestinal wall and disseminate systemically; it is dangerous in patients receiving both HIV and corticosteroids. The larvae carry intestinal bacteria with them, which can cause gram-negative sepsis and bacterial meningitis.
Recurrent Salmonella bacteremia: Bacteremia caused by non-typhoidal Salmonella (Salmonella Typhimurium, S. Enteritidis, etc.) recurs in patients with HIV. Contaminated food is the main source of infection. Bartonellosis (Bartonella): Bacillary angiomatosis caused by Bartonella henselae or B. quintana occurs characteristically in patients with HIV. It presents as cutaneous angiomatous lesions and peliosis hepatis of the liver and spleen. Nocardiosis: Infection of the lung, brain, and skin by Nocardia asteroides occurs in severely immunocompromised patients with HIV.
Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma, progressive multifocal leukoencephalopathy (PML) caused by JC virus, and others may also be included in the B20.8 category, but some are also classified under other codes. Penicillium marneffei (now Talaromyces marneffei) infection is another common fungal opportunistic infection in patients with HIV in Southeast Asia.
B20.8 is an opportunistic infectious disease based on HIV infection and is not a hereditary disease. However, host genetic factors influence HIV susceptibility and defense responses against opportunistic pathogens. HIV-related host genetics apply in the same way as described in detail under B20.7 (CCR5 Δ32, HLA polymorphisms, etc.).
Genetic susceptibility to specific opportunistic pathogens is also important. Regarding Salmonella susceptibility, studies suggest that NRAMP1 (SLC11A1) gene polymorphisms affect the risk of Salmonella bacteremia. NRAMP1 is a protein that inhibits Salmonella proliferation within macrophages, and certain polymorphisms increase susceptibility to Salmonella. Host genetic factors for isosporiasis have not yet been sufficiently studied, but HLA and intestinal immune regulatory genes (IL-17, IL-22, IgA production-related) are expected to be involved. For microsporidia susceptibility, variants in STAT3 and IL-12 pathway genes are under study. Regarding Strongyloides susceptibility, HLA-DRB1, STAT6, and IL-4 receptor polymorphisms may influence the Th2 immune response (required for eliminating Strongyloides) and determine the tendency toward severe infection.
On the pathogen side, the genetic diversity of Isospora, microsporidia, and Strongyloides determines drug resistance and geographic distribution. In particular, Enterocytozoon bieneusi has various genotypes that influence host range and virulence, and some genotypes have low albendazole susceptibility, making treatment difficult.
The frequency of the opportunistic infections included in B20.8 varies greatly by region and pathogen. Isosporiasis, microsporidiosis, and Strongyloides hyperinfection are relatively common in tropical and subtropical regions, while Salmonella bacteremia and bartonellosis are distributed worldwide.
In the pre-ART era, Isospora (Cystoisospora belli) was the cause of chronic diarrhea in about 15-20% (Haiti) and 2-3% (US and Europe) of patients with HIV. The incidence has decreased greatly since ART, but it is still common in regions with low access to ART. Occurrence is concentrated in patients with CD4 <200/μL.
In the pre-ART era, microsporidia were the cause in about 15-30% (tropical regions) and 5-15% (developed countries) of chronic diarrhea in patients with HIV. The incidence has decreased greatly since ART. It is distributed worldwide and occurs mainly in patients with CD4 <50-100/μL.
Strongyloides is estimated to infect about 600 million people worldwide and is especially common in tropical and subtropical regions (sub-Saharan Africa, Southeast Asia, the Caribbean, South America). Strongyloides hyperinfection syndrome in patients with HIV can have a case fatality rate of 50-80%, which makes it clinically important. In Korea, domestic Strongyloides infection is rare, but it can occur in patients with HIV from endemic areas among foreign immigrants, international students, and travelers.
In patients with HIV, non-typhoidal Salmonella bacteremia shows an incidence 100 to 300 times higher than in the general population, and the risk persists after ART in patients with low CD4. In African patients with HIV, the annual incidence of Salmonella bacteremia has been reported to reach 100-200 cases per 1,000 patient-years.
The mechanisms of the other opportunistic infections in B20.8 share a common background of HIV-induced collapse of cell-mediated immunity, with pathogen-specific mechanisms added for each.
From the early stage of infection, HIV rapidly destroys CD4+ T cells (especially Th17 cells) in the lamina propria of the intestinal mucosa. Th17 cells regulate maintenance of intestinal epithelial tight junctions and secretion of antimicrobial peptides through IL-17 and IL-22. Loss of these cells collapses the intestinal mucosal barrier, causing translocation of bacteria and parasites, which is a cause of chronic systemic immune activation. Intestinal parasites such as Isospora, microsporidia, and Cryptosporidium invade the damaged intestinal mucosa more easily and maintain persistent infection.
Strongyloides has a unique life cycle in which larvae re-invade through the intestinal wall (autoinfection). Under normal immunity, the Th2 immune response (IL-4, IL-13, IgE, eosinophils) suppresses autoinfection and keeps the worm burden at a constant level. When this suppression is lost because of the HIV-induced decrease in CD4+ T cells, especially reduced Th2 function, the autoinfection cycle increases rapidly and hyperinfection syndrome develops. In hyperinfection, larvae penetrate the intestinal wall in large numbers and carry intestinal bacteria (gram-negative bacteria) into the bloodstream, causing sepsis.
Under normal immunity, the organism is cleared after Salmonella bacteremia by an immune response (macrophage- and CD4+ T cell-mediated). In patients with HIV, the intracellular killing capacity of macrophages against Salmonella (NRAMP1 pathway) is reduced and CD4+ T cell-mediated immune memory is lost, so recurrent bacteremia occurs. In addition, humoral immunity against Salmonella (specific IgG) is also impaired in patients with HIV.
The opportunistic infections included in B20.8 cause various symptoms depending on the pathogen. Commonly, symptoms specific to each opportunistic infection are superimposed on the systemic symptoms of HIV infection (fever, weight loss, fatigue).
In immunocompromised patients with HIV, Isospora causes watery diarrhea several to dozens of times a day, (cramping) abdominal pain, nausea and vomiting, and fever. Symptoms persist for weeks to months, and without treatment severe dehydration, electrolyte imbalance, and malnutrition occur. When the biliary system is infected, symptoms of cholangitis (right upper quadrant pain, jaundice) may also appear.
In intestinal microsporidiosis, the main symptoms are chronic non-bloody watery diarrhea, abdominal pain, weight loss due to malabsorption, and abdominal distension. Infection with Encephalitozoon intestinalis may also involve extra-intestinal sites such as the bile ducts, kidneys, and paranasal sinuses. In ocular microsporidiosis (keratoconjunctivitis), foreign-body sensation, redness, and decreased vision occur.
In Strongyloides hyperinfection, abdominal pain, nausea and vomiting, diarrhea (including bloody stool), and symptoms of intestinal obstruction occur, and with systemic dissemination of larvae, fever, cough, dyspnea, urticaria, and petechiae (purpura) occur. In gram-negative sepsis due to bacterial translocation, high fever, hypotension, and multiple organ failure may follow. When larvae migrate into the cerebrospinal fluid, bacterial meningitis occurs.
In patients with HIV, Salmonella bacteremia begins with high fever, chills, sweating, and weakness; gastrointestinal symptoms (diarrhea, abdominal pain) may accompany it, but are often absent. Recurrent bacteremia is characteristic. In bartonellosis, angiomatous papules and nodules of the skin (bacillary angiomatosis), fever, and lymphadenopathy appear.
On physical examination, weight loss (wasting), abdominal tenderness, abdominal distension, and hyperactive bowel sounds are commonly found. In Strongyloides hyperinfection, abdominal rigidity, rectal bleeding, and findings of septic shock (hypotension, tachycardia, fever) are possible. In bartonellosis, purple angiomatous skin nodules are characteristic and must be differentiated from Kaposi sarcoma lesions. In isosporiasis, signs of dehydration (decreased skin turgor, dry mouth, oliguria) may appear.
Laboratory findings may include leukocytosis (bacterial infection), eosinophilia (Strongyloides infection; however, in hyperinfection, eosinopenia is characteristic), hypoalbuminemia, elevated CRP/ESR, and positive blood culture (Salmonella bacteremia). Abdominal CT may show bowel wall thickening, bowel dilatation, ascites, and hepatosplenomegaly.
Screening of the general population for the opportunistic infections included in B20.8 is not performed; targeted screening is done in patients with HIV who have specific risk factors. In patients with HIV from Strongyloides-endemic areas (Southeast Asia, sub-Saharan Africa, the Caribbean, South America), or long-term residents of these areas, a Strongyloides serologic test (ELISA, sensitivity ~85%) or stool test must be performed before immunosuppressive treatment (steroids, transplantation). When chronic diarrhea is present in a patient with HIV, perform extensive stool testing including direct stool microscopy (parasite ova and larvae), stool culture (Salmonella), Isospora-specific staining (modified Ziehl-Neelsen, stool morphology examination), and special stains for microsporidia (Modified trichrome, Calcofluor white).
Isosporiasis: Direct stool smear, flotation method, or acid-alcohol-fixed modified Ziehl-Neelsen stain of stool (to identify acid-fast oocysts). Endoscopic small-bowel biopsy shows Cyclospora and Isospora endogenous sporozoites. PCR is useful for improving sensitivity. Microsporidiosis: Spores are identified with Weber's modified trichrome stain (Modified Trichrome Blue) of stool or duodenal fluid. Calcofluor white fluorescent stain. PCR (targeting 18S rRNA) allows species-level differentiation. In tissue, confirmation by Warthin-Starry stain or electron microscopy. Strongyloides: Direct stool smear or the Baermann concentration method (larval detection). Because the sensitivity of a single stool examination is low, repeating the test 3 or more times is recommended. ELISA serologic test (sensitivity 85-90%). In hyperinfection, larvae can also be detected in sputum, BAL, and cerebrospinal fluid. Salmonella bacteremia: Blood culture (high positive rate), stool culture. Perform antibiotic susceptibility testing. Bartonellosis: Skin biopsy (identification of the pathogen with Warthin-Starry silver stain), serum antibody test (IFA), blood PCR.
Isosporiasis: TMP-SMX (160/800 mg) 1 tablet 4 times daily × 10 days, then prophylactic maintenance therapy of 1 tablet twice daily until CD4 recovery. For sulfa hypersensitivity, substitute pyrimethamine + folinic acid or ciprofloxacin. Microsporidiosis (Encephalitozoon intestinalis): Albendazole 400 mg twice daily for 3 weeks or more. Because Enterocytozoon bieneusi responds poorly to albendazole, fumagillin (approved in some countries) or immune recovery by ART is the main treatment. Strongyloides hyperinfection: Ivermectin 200 μg/kg/day orally (repeat 2-day treatment; in hyperinfection, extend to 7-14 days or until stool tests become negative). If oral ivermectin cannot be taken, consider subcutaneous injection or rectal administration. Concurrent broad-spectrum antibiotic treatment for accompanying bacterial sepsis. Salmonella bacteremia: A fluoroquinolone (ciprofloxacin) or ceftriaxone for 4 to 6 weeks or more according to susceptibility results (long-term treatment to prevent recurrence). Maintenance prophylaxis can be stopped when CD4 recovers after ART. In all cases, the key to treatment is early initiation or resumption of ART to promote immune recovery.
Isosporiasis responds well to TMP-SMX treatment, and recurrence-prevention treatment can be stopped when CD4 recovers with ART. For microsporidiosis, immune recovery by ART is the most important treatment, and most cases improve after CD4 recovery. Strongyloides hyperinfection syndrome has a mortality of 50-80% when diagnosis is delayed or when it has progressed to sepsis, so early diagnosis and prompt treatment determine life or death. Salmonella bacteremia is mostly controlled with appropriate antibiotic treatment and ART, but the risk of recurrence is high without CD4 recovery. Overall, CD4 recovery by ART is the most important prognostic determinant of B20.8 opportunistic infections.
The most effective prevention is to keep CD4 high through early initiation and maintenance of ART. Isospora prevention: TMP-SMX 1 tablet/day (CD4 <200/μL, or maintenance after treatment of Isospora). Strongyloides prevention: screening tests before immunosuppressive treatment (steroids, transplantation, chemotherapy) in persons from tropical regions or long-term residents, and prophylactic ivermectin treatment if positive. Salmonella prevention: food safety management (hand washing after handling raw meat and raw eggs, eating cooked food), caution with food when traveling. No walking barefoot in Strongyloides-endemic areas; minimize contact with contaminated soil. Maintaining CD4 at 200/μL or above makes most B20.8 opportunistic infections preventable.
Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. DHHS. 2024. https://clinicalinfo.hiv.gov/
Weller PF, Leder K. Strongyloidiasis. UpToDate. 2024.
Checkley AM, Chiodini PL, Dockrell DH, et al. Eosinophilia in returning travellers and migrants from the tropics: UK recommendations for investigation and initial management. J Infect. 2010;60(1):1-20. DOI: 10.1016/j.jinf.2009.11.003. PMID: 19931551.
Miao YM, Awad-El-Kariem FM, Franzen C, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25(2):124-129. DOI: 10.1097/00042560-200010010-00004. PMID: 11103040.
Feasey NA, Dougan G, Kingsley RA, et al. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. Lancet. 2012;379(9835):2489-2499. DOI: 10.1016/S0140-6736(11)61752-2. PMID: 22587967.
Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32(3):331-351. DOI: 10.1086/318514. PMID: 11170940.
Leder K, Weller PF. Epidemiology, clinical manifestations, and diagnosis of strongyloidiasis. UpToDate. 2024.
Kodjikian L, Fleury J, Roure S, et al. Ocular microsporidiosis in AIDS. Ophthalmology. 2005;112(1):80-84. DOI: 10.1016/j.ophtha.2004.07.027. PMID: 15629821.
WHO. WHO guidelines on management of strongyloidiasis. WHO. 2016. ISBN: 9789241549905.
CDC. Parasites — Cystoisospora. Centers for Disease Control and Prevention. 2024. https://www.cdc.gov/parasites/cystoisospora/